Optimizing recent advances in metastatic renal cell carcinoma

Current Oncology Reports

Volumn 11, Issue 3, 2009, Pages 218-226

  Courtney, Kevin D ^a   Choueiri, Toni K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; AXITINIB; BEVACIZUMAB; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; INTERFERON; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; BLOOD TOXICITY; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DRUG DOSE INCREASE; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY METASTASIS; MUCOSA INFLAMMATION; NEPHRECTOMY; PATHOGENESIS; PERIPHERAL EDEMA; PROTEINURIA; RASH; REVIEW;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65349147015     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0031-5     Document Type: Review

References (49)

1. Golshayan AR, Brick AJ, Choueiri TK: Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: Data from recent studies. Future Oncol 2008, 4:85-92.
2. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005, 353:2477-2490.
3. Coppin C, Le L, Porzsolt F, Wilt T: Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2008, CD006017.
4. Fyfe G, Fisher RI, Rosenberg SA, et al.: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13:688-696.
5. McDermott DF, Atkins MB: Interleukin-2 therapy of metastatic renal cell carcinoma - predictors of response. Semin Oncol 2006, 33:583-587.
6. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999, 353:14-17.
7. Negrier S, Perol D, Ravaud A, et al.: Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: Results of a randomized controlled trial. Cancer 2007, 110:2468-2477.
8. Kaelin WG Jr: The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004, 10:6290S-6295S.
9. Garcia JA: Novel strategies in the management of advanced renal cell carcinoma. In New Treatment Paradigms in Renal Cell Carcinoma. Edited by Bukowski RM. Manhasset, NY: CMPMedica; 2007:95-113.
10. Sansal I, Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004, 22:2954-2963.
11. Hutson TE, Figlin RA: Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park) 2007, 21:1175-1180; discussion 1184, 1187, 1190.
12. Strumberg D, Richly H, Hilger RA, et al.: Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005, 23:965-972.
13. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
14. Motzer RJ, Michaelson MD, Redman BG, et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
15. Motzer RJ, Rini BI, Bukowski RM, et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
16. Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
17. Figlin RA, Hutson TE, Tomczak P, et al.: Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008, 26:aBstract 5024.
18. Le Tourneau CI Faivre S, Serova M, Raymond E: MTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 2008, 99:1197-1203.
19. Hudes G, Carducci M, Tomczak P, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
20. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al.: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 23:832-841.
21. Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
22. Motzer RJ, Escudier B, Oudard S, et al.: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
23. Rini BI, Halabi S, Rosenberg JE, et al.: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-5428.
24. Escudier B, Pluzanska A, Koralewski P, et al.: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
25. Rini BI, Bukowski RM: Targeted therapy for metastatic renal cell carcinoma: A home run or a work in progress? Oncology (Williston Park) 2008, 22:388-396; discussion 396, 402-403, 476 passim.
26. Hutson TE, Davis ID, Machiels JH, et al.: Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008, 26:aBstract 5046.
27. Hutson TE, Davis ID, Machiels JH, et al.: Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2007, 25:5031.
28. Rixe O, Bukowski RM, Michaelson MD, et al.: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 2007, 8:975-984.
29. Feldman DR, Ginsberg MS, Baum M, et al.: Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:aBstract 5100.
30. Sosman JA, Flaherty KT, Atkins MB, et al.: Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008, 26:aBstract 5011.
31. Fischer P, Patel P, Carducci MA, et al.: Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. J Clin Oncol 2008, 26:aBstract 16020.
32. Motzer RJ, Bacik J, Murphy BA, et al.: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
33. Choueiri TK, Garcia JA, Elson P, et al.: Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007, 110:543-550.
34. Choueiri TK, Vaziri SA, Jaeger E, et al.: Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008, 180:860-865; discussion 865-866.
35. Patel PH, Chadalavada RS, Ishill NM, et al.: Hypoxiainducible factor (HIF) 1a and 2a levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 2008, 26:aBstract 5008.
36. Thomas GV, Tran C, Mellinghoff IK, et al.: Hypoxiainducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006, 12:122-127.
37. Cho D, Signoretti S, Dabora S, et al.: Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007, 5:379-385.
38. Figlin R, De Souza PL, McDermott D, et al.: Analysis of pten and hif1-a and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-a [abstract 4477]. Presented at the 99th Annual Meeting of the American Association for Cancer Research Annual Meeting. San Diego, CA; April 12-16, 2008.
39. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ: Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
40. Faber PW, Vaziri SA, Wood L, et al.: Potential non-synonymous single nucleotide polymorphisms (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (MCCRCC) patients (pts) treated with sunitinib. J Clin Oncol 2008, 26:aBstract 5009.
41. Yuan TL, Cantley LC: PI3K pathVay alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
42. Finke JH, Rini B, Ireland J, et al.: Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008, 14:6674-6682.
43. Reckamp KL, Strieter RM, Figlin RA: Chemokines as therapeutic targets in renal cell carcinoma. Expert Rev Anticancer Ther 2008, 8:887-893.
44. Pan J, Burdick MD, Belperio JA, et al.: CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol 2006, 176:1456-1464.
45. Staller P, Sulitkova J, Lisztwan J, et al.: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425:307-311.
46. Pan J, Mestas J, Burdick MD, et al.: Stromal derived factor-1 (SDF-1/ CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 2006, 5:56.
47. Bommi-Reddy A, Almeciga I, Sawyer J, et al.: Kinase requirements in human cells: III. Altered kinase requirements in VHL-/-cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A 2008, 105:16484-16489.
48. Chan DA, Giaccia AJ: Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics. Cell Cycle 2008, 7:2987-2990.
49. Turcotte S, Chan DA, Sutphin PD, et al.: A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 2008, 14:90-102.